| 标题 |
1223TiP A randomized phase III study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG-3098/ENGOT-EN24 |
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of Oncology 作者:B.M. Slomovitz; P. Follana; M.A. Geller; I. Braicu; S. Ghamande; et al 出版日期:2025-09-01 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)